Corrigendum to "Nasopharyngeal carcinoma: Current management, future directions and dental implications" [Oral Oncol 2008;44:617-27] (DOI:10.1016/j.oraloncology.2007.08.003);Nasopharyngeal carcinoma: Current management, future directions and dental implications

Oral Oncology

Volumn 44, Issue 7, 2008, Pages 617-627

  Agulnik, Mark ^a   Epstein, Joel B ^b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Chemotherapy; Immunotherapy; Molecular targeted agents; Nasopharyngeal neoplasm; Oral complications and oral care; Radiotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; LATENT MEMBRANE PROTEIN 1; METHOTREXATE; OXALIPLATIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATINUM DERIVATIVE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RAF PROTEIN; SORAFENIB; STEM CELL FACTOR; TAXANE DERIVATIVE; UFT; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VINCRISTINE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; DENTAL CARE; DYSPHAGIA; HUMAN; HYPOSALIVATION; INFECTION; METASTASIS; MOUTH DISEASE; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION FIELD; RADIATION INJURY; REVIEW; TASTE DISORDER; TRISMUS;

EID: 45449090278     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.01.009     Document Type: Erratum

References (65)

1. Fandi A., Altun M., Azli N., Armand J.P., and Cvitkovic E. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 21 3 (1994) 382-397
2. Chong V.F., and Fan Y.F. Maxillary nerve involvement in nasopharyngeal carcinoma. AJR Am J Roentgenol 167 5 (1996) 1309-1312
3. Huang D.P. Epidemiology of nasopharyngeal carcinoma. Ear Nose Throat J 69 4 (1990) 222-225
4. Jeannel D., Ghnassia M., Hubert A., Sancho-Garnier H., Eschwege F., Crognier E., et al. Increased risk of nasopharyngeal carcinoma among males of French origin born in Maghreb (North Africa). Int J Cancer 54 4 (1993) 536-539
5. Skinner D.W., and Van Hasselt C.A. Nasopharyngeal carcinoma: methods of presentation. Ear Nose Throat J 69 4 (1990) 237-240
6. Epstein J.B., Emerton S., Lunn R., Le N., and Wong F.L. Pretreatment assessment and dental management of patients with nasopharyngeal carcinoma. Oral Oncol 35 1 (1999) 33-39
7. Zheng X., Yan L., Nilsson B., Eklund G., and Drettner B. Epstein-Barr virus infection, salted fish and nasopharyngeal carcinoma. A case-control study in southern China. Acta Oncol 33 8 (1994) 867-872
8. Chapman K.E., and Patton L.L. Nasopharyngeal carcinoma: a 15-year retrospective study. Spec Care Dentist 13 4 (1993) 163-170
9. West S., Hildesheim A., and Dosemeci M. Non-viral risk factors for nasopharyngeal carcinoma in the Philippines: results from a case-control study. Int J Cancer 55 5 (1993) 722-727
10. Perez C., and Brady L. Nasopharynx principles and practice of radiation oncology (1997), Lippincott-Raven, Philadelphia
11. Lin J.C., Wang W.Y., Chen K.Y., Wei Y.H., Liang W.M., Jan J.S., et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. New Engl J Med 350 24 (2004) 2461-2470
12. Leung S.F., Zee B., Ma B.B., Hui E.P., Mo F., Lai M., et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 24 34 (2006) 5414-5418
13. Greene F. AJCC cancer staging manual (2002), Springer, New York
14. Mackie A.M., Epstein J.B., Wu J.S., and Stevenson-Moore P. Nasopharyngeal carcinoma: the role of the dentist in assessment, early diagnosis and care before and after cancer therapy. Oral Oncol 36 5 (2000) 397-403
15. Chen M.S., Lin F.J., Tang S.G., Leung W.M., and Leung W. Clinical significance of cranial nerve deficit in the therapy of nasopharyngeal carcinoma. Brit J Radiol 62 740 (1989) 739-743
16. Cohen S.G., and Quinn P.D. Facial trismus and myofascial pain associated with infections and malignant disease. Report of five cases. Oral Surg Oral Med Oral Pathol 65 5 (1988) 538-544
17. Epstein J.B., and Jones C.K. Presenting signs and symptoms of nasopharyngeal carcinoma. Oral Surg Oral Med Oral Pathol 75 1 (1993) 32-36
18. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(≥N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys 35 3 (1996) 463-469
19. Chua D.T., Nicholls J.M., Sham J.S., and Au G.K. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 59 1 (2004) 11-20
20. Chua D.T., Sham J.S., Choy D., Lorvidhaya V., Sumitsawan Y., Thongprasert S., et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy vs. radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer 83 11 (1998) 2270-2283
21. Hareyama M., Sakata K., Shirato H., Nishioka T., Nishio M., Suzuki K., et al. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer 94 8 (2002) 2217-2223
22. Ma J., Mai H.Q., Hong M.H., Min H.Q., Mao Z.D., Cui N.J., et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 19 5 (2001) 1350-1357
23. Chua D.T., Ma J., Sham J.S., Mai H.Q., Choy D.T., Hong M.H., et al. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: subgroup analysis of two phase III trials. Int J Radiat Oncol Biol Phys 65 5 (2006) 1300-1306
24. Chan A.T., Leung S.F., Ngan R.K., Teo P.M., Lau W.H., Kwan W.H., et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 97 7 (2005) 536-539
25. Chan A.T., Teo P.M., Ngan R.K., Leung T.W., Lau W.H., Zee B., et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 20 8 (2002) 2038-2044
26. Zhang L., Zhao C., Peng P.J., Lu L.X., Huang P.Y., Han F., et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 23 33 (2005) 8461-8468
27. Lin J.C., Jan J.S., Hsu C.Y., Liang W.M., Jiang R.S., and Wang W.Y. Phase III study of concurrent chemoradiotherapy vs. radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21 4 (2003) 631-637
28. Rossi A., Molinari R., Boracchi P., Del Vecchio M., Marubini E., Nava M., et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol 6 9 (1988) 1401-1410
29. Chi K.H., Chang Y.C., Guo W.Y., Leung M.J., Shiau C.Y., Chen S.Y., et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 52 5 (2002) 1238-1244
30. Chan A.T., Teo P.M., Leung T.W., Leung S.F., Lee W.Y., Yeo W., et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 33 3 (1995) 569-577
31. Al-Sarraf M., LeBlanc M., Giri P.G., Fu K.K., Cooper J., Vuong T., et al. Chemoradiotherapy vs. radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16 4 (1998) 1310-1317
32. Al-Sarraf M., LeBlanc M., Giri P.G.S., Fu K., Cooper J., Vuong T., et al. Superiority of five year survival with chemo-radiotherapy (CT-RT) vs. radiotherapy in patients (Pts) with locally advanced nasopharyngeal cancer (NPC). Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) phase III study: final report. Proc Am Soc Clin Oncol 20 (2001) 227a [abstract 905]
33. Hoffman H., Cooper J.S., Weber R., Ang K., Porter K., and Langer C.J. Changing patterns of practice in the management of nasopharynx carcinoma (NPC): analysis of the National Cancer Database (NCDB). Proc Am Soc Clin Oncol 22 (2004) 5501a
34. Wee J., Tan E.H., Tai B.C., Wong H.B., Leong S.S., Tan T., et al. Randomized trial of radiotherapy vs. concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23 27 (2005) 6730-6738
35. Lee A.W., Lau W.H., Tung S.Y., Chua D.T., Chappell R., Xu L., et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23 28 (2005) 6966-6975
36. Lee A.W., Tung S.Y., Chan A.T., Chappell R., Fu Y.T., Lu T.X., et al. Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 66 1 (2006) 142-151
37. Kwong D.L., Sham J.S., Au G.K., Chua D.T., Kwong P.W., Cheng A.C., et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 22 13 (2004) 2643-2653
38. Baujat B., Audry H., Bourhis J., Chan A.T., Onat H., Chua D.T., et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64 1 (2006) 47-56
39. Hunt M.A., Zelefsky M.J., Wolden S., Chui C.S., LoSasso T., Rosenzweig K., et al. Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer. Int J Radiat Oncol Biol Phys 49 3 (2001) 623-632
40. Wolden S., Pfister D., Zelefsky M., Rosenzweig K., Chong L., Kraus D., et al. Intensity-modulated radiation therapy improves locoregional control for nasopharyngeal carcinoma. Proc Am Soc Clin Oncol 21 (2002) 956a
41. Wolden S.L., Chen W.C., Pfister D.G., Kraus D.H., Berry S.L., and Zelefsky M.J. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 64 1 (2006) 57-62
42. Lee N., Xia P., Quivey J.M., Sultanem K., Poon I., Akazawa C., et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53 1 (2002) 12-22
43. Sultanem K., Shu H.K., Xia P., Akazawa C., Quivey J.M., Verhey L.J., et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 48 3 (2000) 711-722
44. Xia P., Fu K.K., Wong G.W., Akazawa C., and Verhey L.J. Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 48 2 (2000) 329-337
45. Kam M.K., Teo P.M., Chau R.M., Cheung K.Y., Choi P.H., Kwan W.H., et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 60 5 (2004) 1440-1450
46. Talmi Y.P., Horowitz Z., Bedrin L., Wolf M., Chaushu G., Kronenberg J., et al. Quality of life of nasopharyngeal carcinoma patients. Cancer 94 4 (2002) 1012-1017
47. Chainani-Wu N., Gorsky M., Mayer P., Bostrom A., Epstein J.B., and Silverman Jr. S. Assessment of the use of sialogogues in the clinical management of patients with xerostomia. Spec Care Dentist 26 4 (2006) 164-170
48. Le Q.T., Tate D., Koong A., Gibbs I.C., Chang S.D., Adler J.R., et al. Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 56 4 (2003) 1046-1054
49. Lu J.J., Shakespeare T.P., Tan L.K., Goh B.C., and Cooper J.S. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma. Head Neck 26 5 (2004) 389-395
50. Pai P.C., Chuang C.C., Wei K.C., Tsang N.M., Tseng C.K., and Chang C.N. Stereotactic radiosurgery for locally recurrent nasopharyngeal carcinoma. Head Neck 24 8 (2002) 748-753
51. Chua D.T., Sham J.S., Leung L.H., and Au G.K. Re-irradiation of nasopharyngeal carcinoma with intensity-modulated radiotherapy. Radiother Oncol 77 3 (2005) 290-294
52. Li J.C., Hu C.S., Jiang G.L., Mayr N.A., Wang J.Z., He X.Y., et al. Dose escalation of three-dimensional conformal radiotherapy for locally recurrent nasopharyngeal carcinoma: a prospective randomised study. Clin Oncol (R Coll Radiol) 18 4 (2006) 293-299
53. Shin S.S., Ahn Y.C., Lim D.H., Park W., and Huh S.J. High dose 3-dimensional re-irradiation for locally recurrent nasopharyngeal cancer. Yonsei Med J 45 1 (2004) 100-106
54. Fandi A., Bachouchi M., Azli N., Taamma A., Boussen H., Wibault P., et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol 18 6 (2000) 1324-1330
55. Ma B.B., Tannock I.F., Pond G.R., Edmonds M.R., and Siu L.L. Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer 95 12 (2002) 2516-2523
56. Leong J.L., Loh K.S., Putti T.C., Goh B.C., and Tan L.K. Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 114 1 (2004) 153-157
57. Chan A.T., Hsu M.M., Goh B.C., Hui E.P., Liu T.W., Millward M.J., et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 23 15 (2005) 3568-3576
58. Chan A.T., Ma B.B., Hui E.P., King A., Kam M.K., Kwan W., et al. Phase II study of gefitinib in metastatic or locoregionally recurrent nasopharyngeal carcinoma (NPC). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings 24 18S (2006) 15509
59. Guang-Wu H., Sunagawa M., Jie-En L., Shimada S., Gang Z., Tokeshi Y., et al. The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. Laryngoscope 110 12 (2000) 2066-2069
60. Chen E., Winquist E., Agulnik M., Chin S., Pond G., Cheiken R., et al. A phase II study of Sorafenib (BAY 43-9006) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC). Eur J Cancer 3 2 (2005) a297
61. Bar-Sela G., Kuten A., Ben-Eliezer S., Gov-Ari E., and Ben-Izhak O. Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach. Mod Pathol 16 10 (2003) 1035-1040
62. Ma B.B., Poon T.C., To K.F., Zee B., Mo F.K., Chan C.M., et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma-a prospective study. Head Neck 25 10 (2003) 864-872
63. Yan J., Fang Y., Huang B.J., Liang Q.W., Wu Q.L., and Zeng Y.X. Absence of evidence for HER2 amplification in nasopharyngeal carcinoma. Cancer Genet Cytogen 132 2 (2002) 116-119
64. Straathof K.C., Bollard C.M., Popat U., Huls M.H., Lopez T., Morriss M.C., et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105 5 (2005) 1898-1904
65. Indudharan R., Valuyeetham K.A., Kannan T., and Sidek D.S. Nasopharyngeal carcinoma: clinical trends. J Laryngol Otol 111 8 (1997) 724-729